Media stories about Aclaris Therapeutics (NASDAQ:ACRS) have trended somewhat positive recently, according to Accern. Accern rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aclaris Therapeutics earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 47.50467273731 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Several equities analysts recently issued reports on ACRS shares. Jefferies Group LLC reaffirmed a “buy” rating and set a $36.00 price objective on shares of Aclaris Therapeutics in a report on Monday, July 31st. BidaskClub cut Aclaris Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Cantor Fitzgerald set a $50.00 price target on Aclaris Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 9th. JMP Securities reissued an “outperform” rating and issued a $39.00 price target on shares of Aclaris Therapeutics in a report on Friday, September 8th. Finally, ValuEngine cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, September 12th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. Aclaris Therapeutics has a consensus rating of “Buy” and an average price target of $39.20.

Shares of Aclaris Therapeutics (NASDAQ:ACRS) opened at $23.32 on Tuesday. Aclaris Therapeutics has a 1 year low of $21.47 and a 1 year high of $33.25.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.63) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.86) by $0.23. The business had revenue of $0.68 million during the quarter, compared to analysts’ expectations of $2.00 million. analysts forecast that Aclaris Therapeutics will post -2.59 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Aclaris Therapeutics (ACRS) Receives Daily Coverage Optimism Rating of 0.16” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/11/28/aclaris-therapeutics-acrs-receives-daily-coverage-optimism-rating-of-0-16.html.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Insider Buying and Selling by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Stock Ratings for Aclaris Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc and related stocks with our FREE daily email newsletter.